Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 26 of 26 entries
Sorted by: Best Match Show Resources per page
Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.

PloS one

Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A.
PMID: 34972132
PLoS One. 2021 Dec 31;16(12):e0261473. doi: 10.1371/journal.pone.0261473. eCollection 2021.

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reaction in cancer patients treated with several cytotoxic anticancer agents including paclitaxel. Duloxetine, an antidepressant known as a serotonin-noradrenalin reuptake inhibitor, is the only agent that has moderate evidence for the...

Cite
Hiramoto S, Asano H, Miyamoto T, et al. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One. 2021;16(12):e0261473doi: 10.1371/journal.pone.0261473.
Hiramoto, S., Asano, H., Miyamoto, T., Takegami, M., & Kawabata, A. (2021). Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PloS one, 16(12), e0261473. https://doi.org/10.1371/journal.pone.0261473
Hiramoto, Shiori, et al. "Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan." PloS one vol. 16,12 (2021): e0261473. doi: https://doi.org/10.1371/journal.pone.0261473
Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One. 2021 Dec 31;16(12):e0261473. doi: 10.1371/journal.pone.0261473. eCollection 2021. PMID: 34972132; PMCID: PMC8719717.
Copy Download .nbib Format: NLM
Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.

PloS one

Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A.
PMID: 34972132
PLoS One. 2021 Dec 31;16(12):e0261473. doi: 10.1371/journal.pone.0261473. eCollection 2021.

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reaction in cancer patients treated with several cytotoxic anticancer agents including paclitaxel. Duloxetine, an antidepressant known as a serotonin-noradrenalin reuptake inhibitor, is the only agent that has moderate evidence for the...

Cite
Hiramoto S, Asano H, Miyamoto T, et al. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One. 2021;16(12):e0261473doi: 10.1371/journal.pone.0261473.
Hiramoto, S., Asano, H., Miyamoto, T., Takegami, M., & Kawabata, A. (2021). Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PloS one, 16(12), e0261473. https://doi.org/10.1371/journal.pone.0261473
Hiramoto, Shiori, et al. "Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan." PloS one vol. 16,12 (2021): e0261473. doi: https://doi.org/10.1371/journal.pone.0261473
Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One. 2021 Dec 31;16(12):e0261473. doi: 10.1371/journal.pone.0261473. eCollection 2021. PMID: 34972132.
Copy Download .nbib Format: NLM
Showing 25 to 26 of 26 entries